Search Results - "Vene, Nina"

Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation by Mavri, Alenka, Vene, Nina, Božič-Mijovski, Mojca, Miklič, Marko, Söderblom, Lisbeth, Pohanka, Anton, Malmström, Rickard E., Antovic, Jovan

“…In some clinical situations, measurements of anticoagulant effect of apixaban may be needed. We investigated the inter- and intra-individual apixaban…”
Get full text

The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation by Božič Mijovski, Mojca, Malmström, Rickard E., Vene, Nina, Antovic, Jovan P., Mavri, Alenka

“…Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed…”
Get full text

Risk of major bleeding in elderly patients with atrial fibrillation on direct oral anticoagulants: real world experience by Šinigoj, Petra, Vene, Nina, Košmelj, Katarina, Mavri, Alenka

“…Background The efficacy and safety of direct oral anticoagulants is well established in patients with atrial fibrillation. However, data on their use in the…”
Get full text

Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry by Vene, Nina, Mavri, Alenka, Gubenšek, Mirjam, Tratar, Gregor, Vižintin Cuderman, Tjaša, Pohar Perme, Maja, Blinc, Aleš

“…Interruption of anticoagulant treatment with warfarin or non-vitamin K antagonist oral anticoagulants (NOAC) represents a vulnerable period with an increased…”
Get full text

High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy by Vene, Nina, Mavri, Alenka, Kosmelj, Katarina, Stegnar, Mojca

“…Atrial fibrillation (AF) is associated with hemostatic abnormalities and increased risk of thrombotic cardiovascular events even during oral anticoagulant…”
Get more information

Procoagulant State in Heart Failure With Preserved Left Ventricular Ejection Fraction by Jug, Borut, Vene, Nina, Salobir, Barbara Guzic, Šebeštjen, Miran, Šabovic, Mišo, Keber, Irena

“…The impact of heart failure with preserved left ventricular ejection fraction (LVEF) on activated hemostasis is still unclear. We sought to compare the…”
Get full text

HORMONE REPLACEMENT THERAPY AND VENOUS THROMBOEMBOLISM by Nina Vene

“…BACKGROUND Oral hormone replacement therapy (HRT) is associated with 2- to 4-fold increased riskof venous thromboembolism (VTE). Therefore, all women…”
Get full text

Prognostic impact of haemostatic derangements in chronic heart failure by Jug, Borut, Vene, Nina, Salobir, Barbara Guzic, Sebestjen, Miran, Sabovic, Miso, Keber, Irena

“…Heart failure is characterised by activation of haemostasis. We sought to explore the prognostic impact of deranged haemostasis in chronic heart failure. In…”
Get more information

Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure by Jug, Borut, Salobir, Barbara Gužič, Vene, Nina, Šebeštjen, Miran, Šabovič, Mišo, Keber, Irena

“…Heart failure is characterized by activation of the immune system which is strongly associated with disease severity and outcome. We sought to compare the…”
Get full text

Clinical guidelines for thrombophilia testing in patients with venous thromboembolism by Alenka Mavri, Tjaša Vižintin Cuderman, Monika Štalc, Mojca Božič, Gregor Tratar, Mirjam Gubenšek, Anja Boc, Marko Miklič, Nina Vene

“…Thrombophilia is a condition that increases susceptibility for the development of venous thromboembolism due to accelerated blood clotting. The article…”
Get full text

Management of antithrombotic therapy in patients undergoing regional anesthesia by Maja Šoštarič, Alenka Mavri, Nina Vene, Peter Poredoš, Nada Kodrič

“…Th e use of antithrombotic drugs increases the risk for the perioperative complications with regional anesthesia. Th e spinal epidural haematoma is a rare but…”
Get full text

Prevention of Venous Thromboembolism in Hip and Knee Arthroplasty by Mario Ponikvar, Nina Vene, Alenka Mavri, Anja Boc, Samo K.Fokter

“…Patients with hip or knee arthroplasty are at a particularly high risk for venous thromboembolism. However, these events are highly preventable. For…”
Get full text

Impact of Asymptomatic Pulmonary Embolism on the Long-Term Prognosis of Patients with Deep Venous Thrombosis by Boc, Anja, Vene, Nina, Košmelj, Katarina, Mavri, Alenka

“…Asymptomatic pulmonary embolism (PE) is present in at least one-third of patients with deep venous thrombosis (DVT). However, knowledge about its influence on…”
Get more information

Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation by Miklič, Marko, Mavri, Alenka, Vene, Nina, Söderblom, Lisbeth, Božič-Mijovski, Mojca, Pohanka, Anton, Antovic, Jovan, Malmström, Rickard E.

“…Background Routine laboratory monitoring of rivaroxaban and dose adjustment relating to exposure is currently not recommended. However, in certain clinical…”
Get full text

Rotational thromboelastometry in ex vivo samples from routine clinical practice patients receiving dabigatran by Božič-Mijovski, Mojca, Vene, Nina, Snoj, Nada, Gradišek, Primož, Mavri, Alenka

Get full text

Unprovoked proximal venous thrombosis is associated with an increased risk of asymptomatic pulmonary embolism by Boc, Anja, Vene, Nina, Štalc, Monika, Košmelj, Katarina, Mavri, Alenka

“…Abstract Introduction Pulmonary embolism (PE) is common in patients with deep venous thrombosis (DVT). The outcome of DVT with concomitant symptomatic PE is…”
Get full text

Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure by Stecher, Adela, Vene, Nina, Mavri, Alenka, Mijovski, Mojca Božič, Krevel, Barbara, Gradišek, Primož

Get full text

Idarucizumab for dabigatran reversal in daily clinical practice: A case series by Vene, Nina, Mavri, Alenka, Božič-Mijovski, Mojca, Gregorič, Minja, Uštar, Katja K., Žerjav, Urša, Gradišek, Primož, Stecher, Adela, Frol, Senta, Nedog, Viljenka, Detkova, Nataliya, Kosi, Iwona E.

“…BACKGROUNDReal-life experience with idarucizumab, which reverses the anticoagulant effect of dabigatran, is currently limited. OBJECTIVETo evaluate efficacy…”
Get full text

Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillationl by Sinigoj, P, Malmstrom, RE, Vene, N, Roenquist-Nii, Y, Bozic-Mijovski, M, Pohanka, A, Antovic, JP, Mavri, A

Get full text

Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations by Božič-Mijovski, Mojca, Malmström, Rickard E, Malovrh, Petra, Antovic, Jovan P, Vene, Nina, Šinigoj, Petra, Mavri, Alenka

“…Direct oral anticoagulant dabigatran was first introduced as a fixed-dose drug without routine coagulation monitoring, but current recommendations suggest that…”
Get more information